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Objective. The impact of the M184V/I mutation on the virological failure (VF) rate in HIV-positive patients with suppressed 
viremia switching to an abacavir/lamivudine/dolutegravir regimen has been poorly evaluated.
Method. This is an observational study from 5 European HIV cohorts among treatment-experienced adults with ≤50 copies/mL 
of HIV-1 RNA who switched to abacavir/lamivudine/dolutegravir. Primary outcome was the time to first VF (2 consecutive HIV-1 
RNA >50 copies/mL or single HIV-1 RNA >50 copies/mL accompanied by change in antiretroviral therapy [ART]). We also ana-
lyzed a composite outcome considering the presence of VF and/or virological blips. We report also the results of an inverse proba-
bility weighting analysis on a restricted population with a prior history of VF on any ART regimen to calculate statistics standardized 
to the disparate sampling population.
Results. We included 1626 patients (median follow-up, 288.5 days; interquartile range, 154–441). Patients with a genotypically 
documented M184V/I mutation (n = 137) had a lower CD4 nadir and a longer history of antiviral treatment. The incidence of VF 
was 29.8 cases (11.2–79.4) per 1000 person-years in those with a previously documented M184V/I, and 13.6 cases (8.4–21.8) in pa-
tients without documented M184V/I. Propensity score weighting in a restricted population (n = 580) showed that M184V/I was not 
associated with VF or the composite endpoint (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.35–4.59 and HR 1.66; 95% CI, 
0.81–3.43, respectively).
Conclusions. In ART-experienced patients switching to an abacavir/lamivudine/dolutegravir treatment, we observed few VFs 
and found no evidence for an impact of previously-acquired M184V/I mutation on this outcome. Additional analyses are required 
to demonstrate whether these findings will remain robust during a longer follow-up.
Key words. ABC/3TC/DTG; M184V/I; treatment-experienced patients; virological failure.
INTRODUCTION
Integrase strand transfer inhibitors have been widely pre-
scribed and represent the preferred first-line antiretroviral 
regimen in most major guidelines for HIV-positive patients 
[1, 2]. In combination with 2 nucleoside reverse transcriptase 
inhibitors (NRTIs), dolutegravir (DTG) was found to be supe-
rior to boosted protease inhibitors (PI/r) or a nonnucleoside 
NRTI-based regimen in large clinical trials [3, 4]. DTG also has 
been very effective in treatment-experienced patients due to 
its high resistance barrier [5, 6]. More recently, a randomized 
trial of rilpivirine-DTG dual therapy in treatment-experienced 
patients was shown to be noninferior for the maintenance of 
viral suppression when compared to continuing conventional 
3-drug combination antiretroviral regimens [7]. However, the 
initial enthusiasm regarding the widespread use of DTG has 
been tempered by a number of factors, including side effects 
such as neuropsychiatric disturbances, emergent resistance 
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when given in monotherapy, and possible teratogenicity in early 
pregnancy [8–10]. Although DTG monotherapy was found to 
be noninferior to combination antiretroviral therapy (ART) in 
the first 24 weeks, virological failure (VF) occurred thereafter 
and led to the emergence of DTG resistance [9]. Similar re-
sults have been found in the DOLAM trial where a higher risk 
of VF was observed with DTG monotherapy compared with 
dual lamivudine (3TC)/DTG and triple ART [11]. At present, 
DTG is not recommended as maintenance monotherapy [12]. 
However, its use in monotherapy was shown to be effective 
in patients conventionally treated during primary HIV infec-
tion and in whom treatment was thereafter simplified to DTG 
monotherapy [13].
Although DTG uptake has occurred at an unprecedented 
pace, the impact of past NRTI mutations in treatment-
experienced patients switching to an abacavir (ABC)/3TC/
DTG regimen has been only partially explored. Furthermore, 
the 2015 changes in the French National Agency for AIDS 
Research resistance algorithms [14] highlighted the risk of the 
impaired efficacy of ABC in the presence of the M184V/I muta-
tion, as previously observed for 3TC. Thus, the clinical decision 
to switch to an ABC/3TC/DTG regimen could be influenced 
by a patient having evidence of harboring a M184V/I muta-
tion, which leads to 3TC resistance and may potentially im-
pair the effectiveness of both 3TC and, to a lesser extent ABC, 
thus resulting in a treatment representing functional DTG 
monotherapy.
We conducted a prospective study using data from 5 large 
HIV cohorts in four European countries (France, Italy, the 
Netherlands and Switzerland) to assess the efficacy of the 
ABC/3TC/DTG regimen in virologically-suppressed, ART-
experienced patients, with or without a previously documented 
M184V/I mutation.
METHODS
Study Design
We conducted an observational longitudinal analysis of pro-
spectively collected data from 5 different HIV European co-
horts: (1) ANRS-CO3 Aquitaine for HIV-positive French 
patients [15]; (2) Antiviral Response Cohort Analysis (ARCA) 
containing data on HIV resistance in Italy [16]; (3) AIDS 
Therapy Evaluation in the Netherlands (ATHENA) [17]; (4) the 
Italian Cohort of Antiretroviral-Naïve Patients (ICONA) [18]; 
and (5) the Swiss HIV Cohort Study (SHCS) [19]. All patients 
provided informed consent for the use of their clinical and labo-
ratory data for research purposes according to country-specific 
requirements. Data from the different sources were exchanged 
and pooled according to the HIV Cohorts Data Exchange 
Protocol standard in a pseudonymized form in compliance with 
national ethical principles and privacy legislation governing the 
individual cohorts [20].
Patient Selection
Observations spanned from when DTG became available in 
each cohort country (January 16, 2014, in the Netherlands; May 
1, 2014, in France; May 8, 2014, in Switzerland; and October 
10, 2014, in Italy) until February 2018. Eligible patients were 
18  years of age or older, treatment-experienced HIV patients 
with least 1 resistance profile available before the start of the 
ABC/3TC/DTG regimen, a plasma HIV-1 RNA level ≤50 
copies/mL at the time of the switch, and at least 1 HIV RNA 
assessment following the start of the ABC/3TC/DTG regimen. 
The selection process was conducted by each cohort according 
to the inclusion criteria, and the cohort-specific data were then 
transferred to the SHCS to be merged and analyzed. Patients 
with a follow-up of less than 30  days and those with missing 
data for the primary outcome were excluded from the analysis.
Virological Characteristics
The presence of M184V/I mutations was established by the 
cumulative resistance profile available before the switch to 
ABC/3TC/DTG, including resistance tests performed before 
any treatment was started for a fraction of patients. Information 
on thymidine analogue mutations (TAMs; M41L, D67N, K70R, 
L210W, T215Y/F, and K219Q/E) before the switch to ABC/3TC/
DTG also was obtained.
Endpoints
The primary objective was to explore the effectiveness of 
ABC/3TC/DTG among treatment-experienced patients with 
or without a documented M184V/I mutation. VF was defined 
as 2 consecutive HIV-1 RNA measurements >50 copies/mL 
or a single HIV-RNA value >50 copies/mL accompanied by a 
change in ART or censoring, whichever occurred first.
As a secondary objective, we considered a composite out-
come combining VF with virological blips (VBs), defined as 
isolated detectable HIV-1 RNA measurements >50 copies/mL 
followed by a viral load (VL) <50 copies/ml.
The following factors were explored as predictors of VF and/
or VBs: age; sex; body mass index; ethnicity; VL before the first 
ART regimen above or below 100 000 copies/mL; CD4 count 
nadir; CD4 count at the time of the switch to ABC/3TC/DTG; 
number of TAMs from pre-ABC/3TC/DTG genotypes; prior 
VFs; years of HIV infection; HIV transmission route; intrave-
nous drug use; HIV infection stage; duration of viral suppres-
sion before the switch to ABC/3TC/DTG; and previous PI or 
integrase inhibitor exposure.
Data Analysis
Kaplan Meier plots/estimators and unweighted and inverse 
probability weighted (IPW) univariate Cox proportional-
hazard models were used to assess the primary and secondary 
outcomes [21, 22]. To calculate the weights, we used multivar-
iate logistic regression modeling of the likelihood of a patient 
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having the M184V/I mutation to calculate the propensity score 
(ê(x)), which indicates the calculated probability of each pa-
tient having the M184V/I mutation based on the following 
confounders: age; sex; body mass index; race; VL before the 
first antiretroviral regimen above or below 100 000 copies/mL; 
CD4 nadir; number of TAMs from pre-ABC/3TC/DTG geno-
types; transmission route; years of HIV infection; months of 
viral suppression before the switch to ABC/3TC/DTG; and pre-
vious protease or integrase inhibitor exposure. The propensity 
scores were then converted to the inverse proportional weights 
where the weight was set as equal to 1/ê(x) for individuals with 
M184V/I and 1/[1- ê(x)] for individuals without the mutation 
[22]. As initial attempts at the weighting procedure yielded 2 
groups that were exceedingly heterogenous (Supplementary 
Figure 1S), we performed the final weighted analysis only on 
the subpopulation of the 580 patients who had failed on an ART 
regimen prior to ABC/3TC/DTG initiation, with and without a 
documented M184V/I mutation.
 With regards to the propensity score distributions, we 
observed an improved overlap between the M184V/I and 
non-M184V/I population when restricted to those with pre-
vious VF, which led to a convergence in their characteristics 
(Supplementary Figure 1S, Supplementary Table S1).
As recommended for weighted survival analyses, the confi-
dence intervals were calculated using robust variance estima-
tions [23, 24].
The secondary objectives were assessed with categorical vari-
ables analyzed by the χ 2 or Fisher exact test, as appropriate, and 
continuous variables by the t or Mann-Whitney test, depending 
on data distribution. Time-at-risk started with the switch to 
ABC/3TC/DTG and ended at the time of the penultimate 
VL measurement where the second reading may occur up to 
6 months after discontinuation of the ABC/3TC/DTG regimen 
or first VF.
A sensitivity analysis was performed by excluding individ-
uals who modified ABC/3TC/DTG treatment because of drug-
related adverse events. Statistical significance was set at a P 
value <.05. Statistical analysis was performed using R version 
3.3.1 on June 21, 2016 (R Studio, Inc, Boston, MA).
RESULTS
Baseline and Patient Characteristics
Table 1 shows the characteristics of 1626 patients who were 
included in the analysis: 778 (47.8%) from SHCS; 460 (28.3%) 
from ATHENA; 168 (10.3%) from the Aquitaine cohort; 
132 (8.2%) from ICONA; and 88 (5.4%) from ARCA. The 
highest prevalence of the M184V/I mutation was found in 
the Aquitaine cohort (37 patients; 22.0%), followed by ARCA 
(14 patients; 15.9%), SHCS (56 patients; 7.2%), ATHENA (24 
patients; 5.2%) and ICONA (6 patients; 4.5%). Overall, 137 
patients had an M184V/I mutation (8.4%) with a ratio of the 
presence or absence of the M184V/I mutation of approxi-
mately 1:11. Median follow-up was 288.5 days (interquartile 
range, 154–441).
Patients with M184V/I were predominantly male, with a 
mean age of 53.3 years. They had a longer duration of HIV in-
fection, ART treatment, and a longer virological suppression 
before the switch to ABC/3TC/DTG compared with patients 
without the M184V/I mutation. Most patients with a M184V/I 
mutation had experienced VF during their previous treatment 
history (127; 92.7%) compared with those without the mutation 
(453; 30.4%).
VFs
We observed 21 (1.29%) VFs among the 1626 patients included 
in the study. Among these, 17 (1.21%) patients had no previ-
ously detected M184V/I mutation and 4 (3%) did (Table 2).
Seventy-five patients in total had a VB, of whom 63 (4.2%) 
were without and 12 (8.8%) had a M184V/I mutation (mean 
HIV-RNA level, 181 [92–269] and 267 [28–563], respectively). 
The incidence of VF after the switch to ABC/3TC/DTG was 
29.8 (11.2–79.4) and 13.6 (8.4–21.8) per 1000 person-years in 
patients with and without M184V/I, respectively. The rate dif-
ference was 16.4 (-13.7–46.2; P  =  .09). Among the 6 patients 
with a genotype available after the VF, no new mutations were 
observed. Genotypic testing was not performed in 13 pa-
tients, because the low VL was followed by an undetectable 
VL and information was missing for the remaining 2 patients 
(Supplementary Table S2).
Risk Factor Analysis (VF)
In the univariate Cox proportional-hazards analyses, the pres-
ence of the M184V/I mutation was not significantly associated 
with a higher risk of failure (hazard ratio [HR], 1.81; 95% confi-
dence interval [CI], 0.60–5.49; P = .29; Figure 1A).
Composite Outcome: Occurrence of VF/VBs
VF or VBs, or both, were observed in 15 of 137 (10.95%) pa-
tients with a documented M184V/I mutation compared to 73 
of 1489 (4.9%) patients in the group with a wild type at this 
position.
The unweighted univariate analysis showed that M184V/I 
had an effect on the increase of the risk of the composite out-
come (HR, 1.92; 95% CI, 1.09–3.35; P  =  .022; Figure 2A). 
However, the propensity score on the total study population 
was not statistically significant (HR, 1.66; 95% CI, 0.93–2.96).
IPW-Adjusted Analysis on a Restricted Population (Patients with Prior VF)
To fulfil the prerequisites for the IPW-adjusted analysis, we 
only performed this particular analysis on the restricted popu-
lation of 580 individuals who had experienced VF on an ART 
regimen prior to ABC/3TC/DTG, which led to a convergence 
of the population characteristics after IPW adjustment (Table 
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3). We observed 12 (2.1%) VFs among those with a previous 
VF before the switch to the ABC/3TC/DTG regimen. In this 
subpopulation, 8 (1.8%) patients had no previous archived 
M184V/I mutation before IPW adjustment, while 4 (3.2%) did 
(Table 4). VF incidence was 32.0 (0.64–63.4) and 10.4 (0.21–
20.60) for those with and without the M184V/I mutation, re-
spectively. The rate difference was 21.7 (-11.4–54.6; P =  .199). 
The unweighted univariate analysis for the patients with prior 
VF also was similar (HR, 1.19; 95% CI, 0.35–4.06; P  =  .781; 
Figure 1B).
In the IPW-adjusted analysis of 580 patients with prior VF, 
results for the primary and secondary outcomes were essen-
tially unchanged, For the primary outcome, the estimated HR 
for patients with the M184V/I mutation was 1.27 (95% CI, 
0.35–4.59; P = .733; Figure 1C) and for the composite outcome 
the estimated HR was 1.66 (95% CI, 0.81–3.43; P = .17).
TAMs
At least 2 TAMs were documented in 42.3% of patients with 
M184V/I compared to 3.3% of those without the mutation 
Table 1. Baseline Characteristics of Patients With or Without an Archived M184V/I Mutation
Baseline Characteristics
 Variables Without M184V/I (N = 1489) With M184V/I (N = 137) P value
Follow up, daysa 307 (95% CI: 298–317) 358 (95% CI: 321–394) .010
Age, yearsa 48.5 (95% CI: 47.9–49.0) 53.3 (95% CI: 51.6–55.0) <.001
Sex, female 319 (21.4%) 42 (30.7%) .017
BMI, kg/m2,a 24.0 (95% CI: 23.6–24.3) 23.5 (95% CI: 22.7–24.2) .230
Time since documented HIV infection, yearsa 10.6 (95% CI: 10.2–10.9) 20.2 (95% CI: 19.2–21.3) <.001
Time since ART initiation, yearsa 8.5 (95% CI: 8.2–8.8) 17.3 (95% CI: 16.5–18.2) <.001
Viral suppression before the switch to ABC/3TC/DTG, monthsa 83.5 (95% CI: 82.5–88.1) 134.0 (95% CI: 126.5–141.5) <.001
Patients with a previous documented VF 453 (30.4%) 127 (92.7%) <.001 
CD4 T-cell count nadir, mm3,a 232 (95% CI: 224–241) 178 (95% CI: 155–201) <.001
CD4 T-cell count at the time of the switch to ABC/3TC/DTG, mm3,a 665 (95% CI: 649–680) 667 (95% CI: 612–722) .929
Viral load before 1st ART regimen, copies/ml, log10 transformeda 4.84 (95% CI: 4.79–4.89) 4.77 (95% CI: 4.54–5.00) .576
Prior AIDS diagnosis 277 (18.6%) 38 (27.7%) .005
At least 2 TAMs 49 (3.3%) 58 (42.3%) <.001
At least 3 TAMs 29 (1.9%) 41 (29.9%) <.001
Distribution of M184V/I by cohort   <.001
Aquitaine 131 (8.8%) 37 (27.0%)  
Antiviral Response Cohort Analysis (ARCA) 74 (5.0%) 14 (10.2%)  
AIDS Therapy Evaluation in the Netherlands (ATHENA) 436 (29.3%) 24 (17.5%)  
Italian Cohort of Antiretroviral-Naïve Patients (ICONA) 126 (8.5%) 6 (4.4%)  
Swiss HIV Cohort Study (SHCS) 722 (48.5%) 56 (40.9%)  
Treatment class before the switch to ABC/3TC/DTG (at any time)    
NNRTI 897 (60.2%) 111 (81.0%) <.001
INSTI 282 (18.9%) 25 (18.2%) .933
PI 1082 (72.7%) 133 (97.1%) <.001
Abbreviations: ABC/3TC/DTG, abacavir/lamivudine/dolutegravir; ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; INSTI, integrase strand transfer inhibitors; IPW, 
inverse probability weighting analysis; NNRTI, nonnucleoside reverse transcriptase inhibitors; PI, protease inhibitor; TAM, thymidine analogue mutations.
a Mean.
Table 2. Virological Primary Outcomes of Patients With or Without M184V/I Mutations Archived in Overall Population
Primary Outcomes (Overall Population)
Outcomes Without M184V/I (N = 1489) With M184V/I (N = 137)  P value
VF 17 (1.21%)  4 (3%) .09
- 2x HIV-RNA >50 copies/mL 10 1 —
- 1x HIV-RNA >50 copies/mL + ABC/3TC/DTG stop 7 3 —
Treatment (ABC/3TC/DTG) discontinued for reasons other than VF 232 (15.6%) 14 (10.2%) .12
VB    
- at least 1 VB during ABC/3TC/DTG treatment  63 (4.2%) 12 (8.8%)  .03
- mean copies/ml (95% CI)  181 (92–269)  267 (-28–563)  .55
Incidence of VF per 1000 person-years 13.6 (8.4–21.8) 29.8 (11.2–79.4)  .09
Abbreviations: ABC/3TC/DTG, abacavir/lamivudine/dolutegravir; CI, confidence interval; VB, virological blips; VF, virological failure.
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Figure 1. Estimated probability of remaining free from virological failure (VF) with (blue) and without (red) the presence of the M184V/I mutation in (A) the overall popu-
lation (P = .295) and in the subgroup population (at least 1 VF before the switch to ABC/3TC/DTG), (B) before (P = .781) and (C) after (e = 0.733) inverse probability weighted 
adjustment.
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Figure 2. Kaplan Meier plots showing probability of remaining free from virological failure (VF) or virological blips with (blue) and without (red) the presence of the M184V/I 
mutation in (A) the overall population (P = .022) and in the subgroup population (at least 1 VF before the switch to ABC/3TC/DTG), (B) before (P = .106) and (C) after (P = .160) 
inverse probability weighted analysis adjustment.
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(Supplementary Table S3). Among the 21 patients who experi-
enced VF, 2 had 3 archived TAMs (D67N, K70R, and K219Q/E 
and M41L, K70R, and K219Q/E), including the M184V/I mu-
tation. One patient had 2 TAMs (D67N and K219Q/E) without 
an archived M184V/I mutation. The remaining 18 patients had 
no archived TAMs.
Sensitivity Analysis
The sensitivity analysis was performed on 489 patients who had 
prior VF after excluding all those who stopped ABC/3TC/DTG 
due to drug-related adverse events. We did not observe any sig-
nificant association between VF and the M184V/I mutation 
(data not shown). In the propensity weighted analysis, the HR 
was 1.61 (95% CI, 0.76–3.39; P = .22).
DISCUSSION
To the best of our knowledge, this study is the largest observa-
tional study to focus on the impact of the M184V/I mutation 
on the risk of VF in virologically-suppressed patients switching 
to ABC/3TC/DTG. Overall, we observed a very low VF rate 
(1.3%) after the switch to ABC/3TC/DTG, with no statistically 
significant difference in the VF incidence among patients with 
or without M184V/I after correction for differences in patient 
characteristics. Furthermore, no new mutations were observed 
in reverse transcriptase or integrase after VF in any of the pa-
tients in which genotyping was successfully performed, with 
the caveat that the genotypic resistance results were available 
for only a minority of patients (6 of 21).
One of the main strengths of our study is the use of an IPW-
adjusted analysis for the population restricted to those with VF 
on a prior regimen [25]. In this multi-cohort study, the charac-
teristics of the groups of patients with or without M184V/I were 
too divergent to allow the use of a standard multivariate Cox 
proportional-hazards analysis. We took into account several 
predictors of VF. Among these, the presence of TAMs was con-
sidered as one of the most relevant. We showed with the IPW 
analysis that the M184V/I mutation had no statistically signifi-
cant effect on VF, including when using the composite outcome 
(although a trend could not be excluded). However, the wide 
confidence intervals observed and the limited follow-up should 
be taken into consideration when interpreting the clinical rele-
vance of our findings. Furthermore, we cannot exclude residual 
confounding given the absence of data on treatment adherence. 
Indeed, precise information about adherence to ART was only 
available for a small part of the data set and patients with or 
without emergence of the M184V/I mutation after VF may have 
had a different behavior with regards to treatment adherence.
Previous studies have addressed the effect of the M184V/I 
mutation on the efficacy of a DTG-containing regimen. 
Although most were small trials (less than 500 patients) 
originating from single cohorts, they all described low VF rates, 
irrespective of the presence of the M184V/I mutation. In the 
study by Gagliardini et al [26], the 3-year probability to remain 
VF-free among treatment-experienced patients on PI- or DTG-
based dual therapy containing lamivudine in the presence or 
absence of the M184V/I mutation was 87.8% and 91.9%, re-
spectively (P =  .32). Furthermore, among 126 patients treated 
with a 3TC/DTG-containing regimen and followed for a me-
dian of 1.3 years, VF was detected in none of 21 patients with 
the M184V/I mutation and in 2 of 105 patients without the mu-
tation. Marcelin et al [27] and Reynes et al [28] reported sim-
ilar results. In both studies, no VF was detected in 59 and 27 
patients, respectively, who switched to a DTG-based regimen, 
despite a high M184V/I prevalence (100% in the first study, 63% 
in the latter).
In a recent phase 3b, open-label, noninferiority, randomized 
clinical trial of 627 patients, DTG was shown to be superior 
Table 4. Virological Primary Outcomes of Patients With or Without Archived M184V/I Mutations in the Subgroup Population (At Least 1 Virological Failure 
Before the Switch to Abacavir/Lamivudine/Dolutegravir), Before and After Inverse Probability of Treatment Weighting Adjustment
Primary Outcomes
Population with Prior VF Population with Prior VF
Before IPW Adjustment After IPW Adjustment
Outcomes
Without M184V/I 
(N = 453)
With M184V/I 
(N = 127) P value
Without M184V/I 
(N = 466)a
With M184V/I 
(N = 114)a
VF:  8 (1.8%)  4 (3.2%)  .306  7 (1.5%)  3 (2.6%)
 2x HIV-RNA >50 copies/mL  5  1   4  1
 1x HIV-RNA >50 copies/mL + ABC/3TC/DTG stop  3  3   3  2
Treatment (ABC/3TC/DTG) discontinued for reasons other than VF  7 (17.22%)  13 (10.24%)  .08  75 (16.1%)  20 (17.5%)
VB      
 at least 1 VB during ABC/3TC/DTG treatment  22 (4.9%)  12 (9.5%)  .083  23 (4.9%)  9 (7.9%)
 mean copies/ml (95% CI) 120 (63–177)  267 (-28–563)  .303 117 (65–169) 307 (-157–772)
Incidence of VF per 1000 person-years 10.4 (0.21–20.60) 32.0 (0.64–63.4) .199 18.5 (4.8–32.3) 27.3 (-3.6–58.2)
Abbreviations: ABC/3TC/DTG, abacavir/lamivudine/dolutegravir; CI, confidence interval; IPW, inverse probability weighting (analysis); VB, virological blips; VF, virological failure.
aSynthetic n values derived from weights. The mean of weights was 1.02 in the group without M184V/I and 0.89 in the group with M184V/I.
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at 48 weeks compared to ritonavir-boosted lopinavir, plus 2 
NRTIs in adults in whom previous first-line ART with a non-
NRTI plus 2 NRTIs had failed [29]. Of note, M184V/I was 
present at baseline in more than 80% of patients and 3TC or 
emtricitabine  (FTC) was included as part of the backbone in 
both arms of the trial. A recent subgroup analysis [30] of this 
study showed that the response rate of DTG also was high when 
3TC or FTC was used in the presence of a M184V/I mutation. 
Similar results were found in more recent studies where DTG 
plus 1 to 2 NRTIs were noninferior to PI-based therapy, regard-
less of the presence of the M184V/I mutation and other NRTI 
mutations at 48 [31] and 78 weeks [32].
Other integrase strand transfer inhibitors, such as elvitegravir 
in the co-formulation elvitegravir/cobicistat/emtricitabine/
tenofovir alafenamide, showed in a prospective open-label 
study to be effective in maintaining viral suppression at week 
12, despite archived M184V/I mutations [33].
An association between low-level viremia (considered as 
intermittent episodes of VBs) and subsequent VF, inadequate 
CD4 recovery, and the development of drug resistance have 
been demonstrated in a previous study [34–36]. More recently, 
Hermans et al [37] showed that VBs (defined as the occurrence 
of 1 viral load measurement of 51–999 copies per mL during 
ART, followed by virological suppression) might be associated 
with a 2.6-fold higher HR for VF. Similar results were shown by 
Young et al where an increase of HR 1.09 of viral rebound was 
detected for every magnitude blip increase of 100 copies/ml in 
naïve patients [38]. Our study is more comparable to the latter 
1 in terms of the VF definition. Although the unweighted uni-
variate analysis showed that M184V/I had a significant effect 
on the increase of the risk of the composite outcome, including 
both VBs and VF, this effect was no longer statistically signifi-
cant in the IPW analysis.
Our study has several limitations. First, despite the fact that 
our study used data from 5 cohorts, the number of patients who 
developed VF during follow-up was small overall. Of note, our 
VF definition was particularly conservative, considering that 
for 13 patients a genotypic testing was not performed due to a 
limited VL, followed by an undetectable VL. In these cases, we 
probably identified a low-level viremia more than a clinically 
relevant true VF. A longer follow-up and additional data from 
more patients are needed before more definite conclusions can 
be drawn. It is also likely that patients with NRTI mutations in 
these cohorts are those who were treated with less potent regi-
mens in the early days of highly active ART and perhaps were 
less compliant. Finally, a so-called “indication bias” may have 
occurred as physicians tended to prescribe a single pill regimen 
in patients with documented resistant mutations only if they 
were confident about patient adherence.
In conclusion, in this large international prospective study, 
we found an extremely low rate of VF among treatment-
experienced patients receiving an ABC/3TC/DTG regimen, 
irrespective of the presence of a M184V/I mutation. Additional 
analyses are required to demonstrate whether these findings 
will remain robust during an extended observation period.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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and J.  Veenstra HIV nurse consultants: C.J. Brouwer, G.F. Geerders, 
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R.  Regez (coordinator) Radboudumc, Nijmegen HIV treating physicians: 
R. van Crevel, M. Keuter, A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. 
Dofferhoff, and J.  Hoogerwerf HIV nurse consultants: K.J.T. Grintjes-
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Gisolf, R.J. Hassing, and M. Claassen HIV nurse consultants: G. ter Beest, 
P.H.M. van Bentum, and N. Langebeek HIV clinical virologists/chemists: 
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L.M.M.  van der Prijt and J.  van der Swaluw Data collection: N.  Bermon 
HIV clinical virologists/chemists: W.A.  van der Reijden, R.  Jansen, B.L. 
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HIV treating physicians: D.W.M. Verhagen HIV nurse consultant: M. van 
Wijk Universitair Medisch Centrum Groningen, Groningen HIV treating 
physicians: W.F.W. Bierman, M.  Bakker, J.  Kleinnijenhuis, E.  Kloeze, 
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F. Paling, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, L. van de Sande, M. Schoorl, 
E. Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, and E.C. Witte Patient 
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